GeneCoda® Publishes Public Biotech CEO and CFO Compensation Report Organized by Company Stage

RTP, NC, July 27, 2026 — GeneCoda® Executive & Professional Search, a life sciences-focused retained executive search and leadership advisory firm, today announced the publication of its new report, Public Biotech CEO and CFO Compensation by Company Stage.

The report examines how reported CEO and CFO compensation changes as public biotechnology companies progress from clinical development toward commercialization. Using source-traceable compensation disclosures from SEC-filed proxy statements, the analysis organizes companies into clinical-stage, late-stage or near-commercial, and commercial or commercial-transition groups.

The findings show that executive compensation rises as operating complexity increases. Median reported CEO total compensation increases from approximately $4.9 million among clinical-stage companies to $9.1 million among commercial and commercial-transition companies. Median CFO total compensation rises from approximately $2.0 million to $3.4 million across the same stages.

“Compensation benchmarking becomes less reliable when all public biotechnology companies are treated as though they present the same leadership mandate,” said Don Alexander, President and Managing Director of GeneCoda®. “A company preparing for pivotal development, launch, or first commercial revenue places different demands on its CEO and CFO than an earlier-stage organization. The purpose of this report is to provide a more useful starting point for those discussions.”

The six-page report includes median and percentile compensation ranges, cash compensation, equity as a share of total compensation, and sample sizes for each benchmark. It also explains why transition years, partial-year appointments, special awards, severance, and large-company controls may need to be separated from primary comparisons.

GeneCoda® developed the report as part of its expanding public biotech executive compensation intelligence capability. The underlying approach emphasizes filed-source data, explicit treatment of non-comparable observations, and peer-set judgment rather than reliance on broad public-company averages.

The report is intended to support initial discussions involving executive hiring, offer calibration, retention, succession planning, compensation benchmarking, and board review. It provides directional public-company Named Executive Officer compensation intelligence and is not presented as a formal compensation survey or precise market-clearing standard.

The complimentary report is available through GeneCoda® at Public Biotech CEO and CFO Compensation by Company Stage.